Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)
Shots:
- Monte Rosa and Novartis entered into a global license agreement for VAV1 molecular glue degraders, incl. MRT-6160, under P-I trial for immune conditions. Novartis will obtain exclusive rights to develop and commercialize MRT-6160 and other VAV1 MGDs, starting with P-II trials, while Monte Rosa will complete the ongoing P-I trial
- Monte Rosa will receive $150M upfront, with potential milestones of up to $2.1B beginning upon P-II trials initiation and tiered royalties on non-U.S. sales. Monte Rosa will co-fund P-III trial development and share manufacturing and commercialization-related profits and losses for MRT-6160 in the U.S.. The deal is subject to standard closing conditions, including regulatory clearance
- Through financial resources provided by this agreement, Monte Rosa expects to extend operational runways and further leverage of QuEEN discovery engine
Ref: Monte Rosa | Image: Monte Rosa & Novartis
Related News:- Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
